- IP Group said it has noted that Diurnal Group confirmed the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to the European Commission recommending Alkindi as replacement therapy for paediatric adrenal insufficiency (AI).

Diurnal is a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases in which IP Group holds a direct undiluted beneficial stake of 44.7%.

At 1:18pm:

[LON:DNL] Diurnal Group Plc share price was +2.5p at 146p

[LON:IPO] IP Group PLC share price was -1p at 144p

Story provided by